The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells
Open accessAbstract
BACKGROUND: MicroRNA-34a (miR-34a) is a transcriptional target of p53 and is down-regulated in pancreatic cancer. This study aimed to investigate the functional significance of miR-34a in pancreatic cancer progression through its epigenetic restoration with chromatin modulators, demethylating agent 5-Aza-2'-deoxycytidine (5-Aza-dC) and HDAC inhibitor Vorinostat (SAHA). METHODOLOGY/PRINCIPAL FINDINGS: Re-expression of miR-34a in human pancreatic cancer stem cells (CSCs) and in human pancreatic cancer cell lines upon treatment with 5-Aza-dC and SAHA strongly inhibited the cell proliferation, cell cycle progression, self-renewal, epithelial to mesenchymal transition (EMT) and invasion. In pancreatic CSCs, modulation of miR-34a induced apoptosis by activating caspase-3/7. Treatment of pancreatic CSCs with the chromatin-modulating agents resulted in the inhibition of Bcl-2, CDK6 and SIRT1, which are the putative targets of miR-34a. MiR-34a upregulation by these agents also induced acetylated p53, p21(WAF1), p27(KIP1) and PUMA in pancreatic CSCs. Inhibition of miR-34a by antagomiR abrogates the effects of 5-Aza-dC and SAHA, suggesting that 5-Aza-dC and SAHA regulate stem cell characteristics through miR-34a. In CSCs, SAHA inhibited Notch pathway, suggesting its suppression may contribute to inhibition of the self-renewal capacity and induction of apoptosis. Interestingly, treatment of pancreatic CSCs with SAHA resulted in the inhibition of EMT with the transcriptional up-regulation of E-Cadherin and down-regulation of N-Cadherin. Expression of EMT inducers (Zeb-1, Snail and Slug) was inhibited in CSCs upon treatment with SAHA. 5-Aza-dC and SAHA also retard in vitro migration and invasion of CSCs. CONCLUSIONS: The present study thus demonstrates the role of miR-34a as a critical regulator of pancreatic cancer progression by the regulating CSC characteristics. The restoration of its expression by 5-Aza-dC and SAHA in CSCs will not only provide mechanistic insight and therapeutic targets for pancreatic cancer but also promising reagents to boost patient response to existing chemotherapies or as a standalone cancer drug by eliminating the CSC characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Sharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
Notch signalling: a simple pathway becomes complex
Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620 · cited 1×
“The activated Notch-ICD translocates into the nucleus and interacts with the transcription factor CSL/ RBP-Jk and the co-activator Mastermind (MAM) to activate target genes such as Hes1 and Hes5 [35,36], and Hes expression can therefore be used as a read out for Notch activity [37].”
BackgroundTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Garzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
miRNAs, Cancer, and Stem Cell Division
Croce, C. M., & Calin, G. A. (2005) · Cell · doi:10.1016/j.cell.2005.06.036 · Cited by 1,329
MicroRNA control of signal transduction
Inui, M., Martello, G., & Piccolo, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2868 · Cited by 1,272
HES and HERP families: Multiple effectors of the notch signaling pathway
Iso, T., Kedes, L., & Hamamori, Y. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10208 · Cited by 1,238
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
Welch, C., Chen, Y., & Stallings, R. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210293 · Cited by 805
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
MicroRNAs — the micro steering wheel of tumour metastases
Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S., & Calin, G. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2619 · Cited by 749
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death
Schickel, R., Boyerinas, B., Park, S.-M., & Peter, M. E. (2008) · Oncogene · doi:10.1038/onc.2008.274 · Cited by 719
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
Notch signaling in the mammalian central nervous system: insights from mouse mutants
Yoon, K., & Gaiano, N. (2005) · Nature Neuroscience · doi:10.1038/nn1475 · Cited by 587
Wang, J., Chen, J., Chang, P., LeBlanc, A., Li, D., Abbruzzesse, J. L., Frazier, M. L., Killary, A. M., & Sen, S. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0094 · Cited by 559
microRNAs join the p53 network — another piece in the tumour-suppression puzzle
He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2232 · Cited by 547
MicroRNAs: Novel Biomarkers for Human Cancer
Bartels, C. L., & Tsongalis, G. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112805 · Cited by 529
MiR-34, SIRT1, and p53: The feedback loop
Yamakuchi, M., & Lowenstein, C. J. (2009) · Cell Cycle · doi:10.4161/cc.8.5.7753 · Cited by 468
Pancreatic cancer: understanding and overcoming chemoresistance
Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., & Sarkar, F. H. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.188 · Cited by 364
Notch and cancer: a double-edged sword
Koch, U., & Radtke, F. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7164-1 · Cited by 333
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells
Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.086 · Cited by 331
miRNA control of tumor cell invasion and metastasis
Baranwal, S., & Alahari, S. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25014 · Cited by 316
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
Shankar, S., Nall, D., Tang, S.-N., Meeker, D., Passarini, J., Sharma, J., & Srivastava, R. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016530 · Cited by 304
Self-citationEpigenetic Inactivation of the miR-124-1 in Haematological Malignancies
Wong, K. Y., So, C. C., Loong, F., Chung, L. P., Lam, W. W. L., Liang, R., Li, G. K. H., Jin, D.-Y., & Chim, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019027 · Cited by 247
Identification of Human Pancreatic Cancer Stem Cells
Li, C., Lee, C. J., & Simeone, D. M. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-59745-280-9_10 · Cited by 227
Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas
Immervoll, H., Hoem, D., Sakariassen, P. Ø., Steffensen, O. J., & Molven, A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-48 · Cited by 206
Mullendore, M. E., Koorstra, J.-B., Li, Y.-M., Offerhaus, G. J., Fan, X., Henderson, C. M., Matsui, W., Eberhart, C. G., Maitra, A., & Feldmann, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2004 · Cited by 188
Katoh, M., & Katoh, M. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.4.681 · Cited by 184
Başak, O., & Taylor, V. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05370.x · Cited by 170
Epigenetic inactivation of the miR-34a in hematological malignancies
Chim, C. S., Wong, K. Y., Qi, Y., Loong, F., Lam, W. L., Wong, L., Jin, D., Costello, J., & Liang, R. H. S. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq033 · Cited by 157
Fandy, T. E., Shankar, S., Ross, D. D., Sausville, E. A., & Srivastava, R. K. (2005) · Neoplasia · doi:10.1593/neo.04655 · Cited by 156
Self-citationEpigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer
Shankar, S., Ganapathy, S., & Srivastava, R. K. (2007) · Frontiers in bioscience · doi:10.2741/2446 · Cited by 148
Self-citationPancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery
Li, J., Wientjes, M. G., & Au, J. L. ‐. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9181-5 · Cited by 124
The Notch Signaling Pathway Is Related to Neurovascular Progression of Pancreatic Cancer
chler, P. B., Gazdhar, A., Schubert, M., Giese, N. A., Reber, H. A., Hines, O. J., Giese, T., Ceyhan, G. R. O., ller, M. M., chler, M. W. B., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000189115.94847.f1 · Cited by 103
MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?
Voorhoeve, P. M. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.09.003 · Cited by 84
Shankar, S., Singh, T. R., Fandy, T. E., Luetrakul, T., Ross, D. D., & Srivastava, R. K. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.16.6.1125 · Cited by 83
Self-citationKimura, K., Satoh, K., Kanno, A., Hamada, S., Hirota, M., Endoh, M., Masamune, A., & Shimosegawa, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00369.x · Cited by 72
Translating MicroRNA Discovery Into Clinical Biomarkers in Cancer
Waldman, S. A., & Terzic, A. (2007) · JAMA · doi:10.1001/jama.297.17.1923 · Cited by 67
MicroRNAs as Cancer Players: Potential Clinical and Biological Effects
Bandrés, E., Agirre, X., Ramírez, N., Zárate, R., & García‐Foncillas, J. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0544 · Cited by 65
Kawahira, H., Kobayashi, S. S., Kaneko, K., Asano, T., & Ochiai, T. (2000) · PubMed · Cited by 61
Shankar, S., Davis, R. B., Singh, K. P., Kurzrock, R., Ross, D. D., & Srivastava, R. K. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1004 · Cited by 59
Self-citationMicroRNAs in mammalian development and tumorigenesis
O'Rourke, J. R., Swanson, M. S., & Harfe, B. D. (2006) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20071 · Cited by 48
Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy
Azmi, A. S., Philip, P. A., Aboukameel, A., Wang, Z., Banerjee, S., Zafar, S. F., Goustin, A. S., Almhanna, K., Yang, D., Sarkar, F. H., et al. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791190229 · Cited by 42
Trp53 Deletion Stimulates the Formation of Metastatic Pancreatic Tumors
Morton, J. P., Klimstra, D. S., Mongeau, M. E., & Lewis, B. C. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070778 · Cited by 33
Hu, Y.-X., Watanabe, H., Ohtsubo, K., Yamaguchi, Y., Ha, A., Motoo, Y., Okai, T., & Sawabu, N. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690466 · Cited by 23
Notch Signaling: Where Pancreatic Cancer and Differentiation Meet?
Jean–Paul De La, O., & Murtaugh, L. C. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.022 · Cited by 15
Cited by
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Bernardo, B. C., Gao, X.-M., Winbanks, C. E., Boey, E. J. H., Tham, Y. K., Kiriazis, H., Gregorevic, P., Obad, S., Kauppinen, S., Du, X.-J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206432109 · Cited by 429
Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F., & Papaccio, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 395
Metadata
- Authors
- Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-31
- Volume
- 6
- Issue
- 8
- Pages
- e24099
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2033320521
- Cited by
- 256
- References
- 51
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.